Market Research Logo

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Review, H1 2016

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Review, H1 2016’, provides in depth analysis on Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted pipeline therapeutics.

The report provides comprehensive information on the Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24)
  • The report reviews Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) Overview
Therapeutics Development
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Stage of Development
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Therapy Area
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Indication
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Companies
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Companies Involved in Therapeutics Development
FibroGen, Inc.
RXi Pharmaceuticals Corporation
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Drug Profiles
FG-3019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Dormant Projects
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Discontinued Products
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Featured News & Press Releases
Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
Mar 11, 2016: FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer
Jan 06, 2016: FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular
Nov 05, 2015: Edison Initiates Coverage on RXi Pharmaceuticals
Nov 05, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 1/2 Trial in Ophthalmology with RXI-109 for Retinal Scarring
Oct 15, 2015: RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109
Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting
Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by FibroGen, Inc., H1 2016
Pipeline by RXi Pharmaceuticals Corporation, H1 2016
Dormant Projects, H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report